2 hours ago · Global
Breakthrough PTSD treatment achieves 68% remission rate in clinical trial
What's happening
SignalsMonitor is following this as a health story. ScienceDaily Health and ScienceDaily Top News are the outlets attached to this story. The reports are tied to Global. The first report grouped here was at 23 Oct 2026, 11:02 UTC. 2 material updates are listed in the timeline. The headline in use is “Breakthrough PTSD treatment achieves 68% remission rate in clinical trial”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health…
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by ScienceDaily Top News
Breakthrough PTSD treatment achieves 68% remission rate in clinical trial
- Picked up by ScienceDaily Health
Breakthrough PTSD treatment achieves 68% remission rate in clinical trial
Same story, different outlets
2 headlinesEach line is that outlet's headline. The article stays on the publisher's site.
- ScienceDaily HealthBreakthrough PTSD treatment achieves 68% remission rate in clinical trial
- ScienceDaily Top NewsBreakthrough PTSD treatment achieves 68% remission rate in clinical trial